Is lipoxin A4 an effective treatment on fat embolism syndrome by attenuating pro-inflammatory response?

Abstract

Fat embolism syndrome (FES) is characterized by high mortality and lack of effective treatment, the symptomatic therapy is most used to relieve clinical symptoms. Some studies have shown that inflammation is one of the main pathogeneses of FES. Lipoxin A4 is an endogenous-derived anti-inflammatory substance which was discovered recently. It can alleviate inflammatory response and promote inflammation resolution, and is referred as brake signal of inflammation. Therefore we hypothesize that lipoxin A4 may have a remission and therapeutic effect on FES by attenuating FES-induced inflammatory responses.

• Authors: Hui Zhang, Aizhong Wang, Tao Xu, Junfeng Zhang, Wei Jiang, Fangfang Niu, Hong Xie
• Journal: Medical hypotheses (Med Hypotheses) Vol. 122 Pg. 176-179 (Jan 2019) ISSN: 1532-2777 [Electronic] United States
• PMID: 30593406 (Publication Type: Journal Article)
• Copyright: Copyright © 2018 Elsevier Ltd. All rights reserved.

Chemical References

• FPR2 protein, human
• Fatty Acids, Nonesterified
• Lipoxins
• Receptors, Formyl Peptide
• Receptors, Lipoxin
• lipoxin A4

Topics

• Animals
• Embolism, Fat (drug therapy, metabolism)
• Fatty Acids, Nonesterified (metabolism)
• Humans
• Inflammation
• Lipoxins (pharmacology, therapeutic use)
• Male
• Rats
• Rats, Sprague-Dawley
• Receptors, Formyl Peptide (metabolism)
• Receptors, Lipoxin (metabolism)
• Signal Transduction
• Wound Healing